Clinical Trial Update: Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3) [Phase 3]

View source ↗

Summary

Phase 3 trial assessing Nyxol (0.75% phentolamine ophthalmic solution) for reversing pharmacologically-induced mydriasis; trial completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dilation of Pupil
• Mydriasis

Drugs mentioned

• Nyxol (phentolamine ophthalmic solution 0.75%)

Snippet

Sponsor: Ocuphire Pharma, Inc. | Conditions: Mydriasis, Dilation | Phase 3 | Status: COMPLETED | Results posted: 2023-08-01